Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study

PURPOSE: During treatment with tyrosine kinase inhibitors, such as sunitinib, patients experience treatment and/or disease-related symptoms. Although application of patient-reported outcome measures (PROMs) enhances early recognition of symptoms, early clinical trials are focused on symptom severity...

Descripción completa

Detalles Bibliográficos
Autores principales: Koldenhof, J. J., Lankheet, N. A. G., Steeghs, N., Teunissen, S. C. C. M., Witteveen, P. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018583/
https://www.ncbi.nlm.nih.gov/pubmed/29464389
http://dx.doi.org/10.1007/s00520-018-4075-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018583/
https://www.ncbi.nlm.nih.gov/pubmed/29464389
http://dx.doi.org/10.1007/s00520-018-4075-7

Ejemplares similares